ArticleOncotarget2021

Head to head evaluation of second generation ALK inhibitors brigatinib and alectinib as first-line treatment for ALK+ NSCLC using an

Enric Carcereny et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.